Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | POLA1 | P09884 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711237 | 0.88 | ALDH1A1 (0.46) | ALDH1A1LMNACYP3A4OPRM1OPRK1 | |
| SCHEMBL1495880 | 0.86 | ESR2 (0.58) | ALDH1A1LMNACYP3A4ESR1ESR2 | |
| SCHEMBL29890280 | 0.86 | ESR2 (0.58) | ALDH1A1LMNACYP3A4ESR1ESR2 | |
| SCHEMBL30701838 | 0.78 | RXRA (0.49) | ALDH1A1LMNACYP3A4 | |
| SCHEMBL1360287 | 0.78 | RXRA (0.49) | ALDH1A1LMNACYP3A4 | |
| SCHEMBL29646235 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNACYP3A4OPRM1OPRK1 | |
| SCHEMBL218608 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNACYP3A4OPRM1OPRK1 | |
| SCHEMBL29646238 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNACYP3A4OPRM1OPRK1 | |
| SCHEMBL12442825 | 0.77 | OPRM1 (0.47) | ALDH1A1LMNACYP3A4OPRM1OPRK1 | |
| SCHEMBL13899941 | 0.77 | ESR1 (0.54) | ALDH1A1LMNACYP3A4OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334376-A1 | CAPPED BISPHENOL POLYETHER OLIGOMER AND COMPOSITION, METHOD OF MANUFACTURE, AND ARTICLES MADE THEREFROM | SHPP Global Technologies B.V. (NL) | 2024-03-13 | — | — | EP | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013096971-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-1896465-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | Takeda Cambridge Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
| US-4510337-A | REACTION OF PHENOLS WITH ISOPRENE OR 2,3-DIMETHYL-1,3-BUTADIENE IN THE PRESENCE OF PHOSPHORIC ACID | PHILLIPS PETROLEUM COMPANY (US) | 1985-04-09 | — | — | US | disclosed |
| US-4510337-A | REACTION OF PHENOLS WITH ISOPRENE OR 2,3-DIMETHYL-1,3-BUTADIENE IN THE PRESENCE OF PHOSPHORIC ACID | PHILLIPS PETROLEUM COMPANY (US) | 1985-04-09 | — | — | US | disclosed |
| US-4510337-A | REACTION OF PHENOLS WITH ISOPRENE OR 2,3-DIMETHYL-1,3-BUTADIENE IN THE PRESENCE OF PHOSPHORIC ACID | PHILLIPS PETROLEUM COMPANY (US) | 1985-04-09 | — | — | US | disclosed |
| US-4107324-A | ARTHROPODICIDES, FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | GNRHR, GHRHR, FSHR | ALDH1A1 4595/4885LMNA 2647/4885CYP3A4 3687/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3733/4885LMNA 4214/4885CYP3A4 3854/4885 |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | GFPT1, NUDT1, INF2 | ALDH1A1 1971/4885LMNA 4617/4885CYP3A4 242/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 3733/4885LMNA 4214/4885CYP3A4 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.